Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
International Journal of Clinical Pharmacy · 2024
DOI: 10.1007/s11096-024-01802-1 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Wenwang Lang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China. 290702062@qq.com. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Tislelizumab combined with chemotherapy has shown significant clinical benefits in improving overall survival compared to chemotherapy alone for patients with extensive-stage small-cell lung cancer (ES-SCLC). AIM: This study aimed to evaluate the cost-effectiveness of tislelizumab plus chemotherapy versus standard chemotherapy as a first-line treatment for ES-SCLC from the US payer perspective and the perspective of the Chinese healthcare system. METHOD: We conducted an economic evaluation using a Markov state-transition model, reflecting the US payer perspective and the perspective of the Chinese healthcare system. Baseline patient characteristics and essential clinical data were obtained from the RATIONALE-312 trial. The costs and utilities were derived from open-access databases and published literature. The primary outcomes measured included quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). Uncertainties in the model were addressed by probabilistic sensitivity analysis (PSA) and one-way sensitivity analysis (OWSA). RESULTS: In the base-case analysis, the addition of tislelizumab to chemotherapy provided an incremental gain of 0.16 QALYs at an additional cost of $7430.73, resulting in an ICER of $46,132.33 per QALY. Although above the willingness-to-pay (WTP) threshold of China of $38,042.49 per QALY, the cost-effectiveness was marginal, with an INHB of - 0.03 QALYs and an INMB of $- 1303.06. In the US, despite a slightly higher effectiveness gain of 0.28 QALYs, the increased cost of $45,157.35 resulted in an unfavorable ICER of $163,885.06 per QALY, exceeding the US WTP threshold of $150,000.00. PSA showed probabilities of cost-effectiveness of tislelizumab plus chemotherapy at 17.18% in China and 40.41% in the US. CONCLUSION: Tislelizumab combined with chemotherapy was not a cost-effective first-line treatment option for ES-SCLC in China or the US; however, the margin of cost-effectiveness was narrow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China. 290702062@qq.com.
- Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
- Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
- Department of Pulmonary and Critical Care Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
Förderung
- Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region
Zitieren
APA
Lang, W., Ai, Q., He, Y., Pan, Y., Jiang, Q., Ouyang, M., & Sun, T. (2024). Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01802-1
Vancouver
Lang W, Ai Q, He Y, Pan Y, Jiang Q, Ouyang M, et al. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01802-1
BibTeX
@article{Lang2024,
author = {Lang, Wenwang and Ai, Qi and He, Yulong and Pan, Yufei and Jiang, Qinling and Ouyang, Ming and Sun, Tianshou},
title = {Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China},
journal = {International Journal of Clinical Pharmacy},
year = {2024},
doi = {10.1007/s11096-024-01802-1}
}
EUVIMED